Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone510-906-4600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions
What is Pulse Biosciences' stock symbol?
Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."
How were Pulse Biosciences' earnings last quarter?
Pulse Biosciences Inc (NASDAQ:PLSE) posted its quarterly earnings data on Thursday, February, 7th. The company reported ($0.51) earnings per share (EPS) for the quarter. View Pulse Biosciences' Earnings History.
When is Pulse Biosciences' next earnings date?
What price target have analysts set for PLSE?
1 brokers have issued 12 month price objectives for Pulse Biosciences' stock. Their forecasts range from $27.00 to $27.00. On average, they expect Pulse Biosciences' stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 38.9% from the stock's current price. View Analyst Price Targets for Pulse Biosciences.
What is the consensus analysts' recommendation for Pulse Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulse Biosciences.
Has Pulse Biosciences been receiving favorable news coverage?
Press coverage about PLSE stock has been trending neutral on Thursday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pulse Biosciences earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the stock's share price in the immediate future.
Who are some of Pulse Biosciences' key competitors?
Some companies that are related to Pulse Biosciences include Mazor Robotics (MZOR), Atrion (ATRI), Cardiovascular Systems (CSII), Nevro (NVRO), K2M Group (KTWO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Luminex (LMNX), Cryolife (CRY), Orthofix Medical (OFIX), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), OraSure Technologies (OSUR) and Orthopediatrics (KIDS).
What other stocks do shareholders of Pulse Biosciences own?
Who are Pulse Biosciences' key executives?
Pulse Biosciences' management team includes the folowing people:
- Mr. Darrin R. Uecker, Pres, CEO & Director (Age 53)
- Mr. Brian B. Dow, CFO, Sr. VP, Treasurer & Sec. (Age 50)
- Dr. Richard Nuccitelli Ph.D., Chief Science Officer
- Dr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy
- Mr. Edward A. Ebbers, Exec. VP & GM of Dermatology (Age 59)
When did Pulse Biosciences IPO?
(PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.
Who are Pulse Biosciences' major shareholders?
Pulse Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.98%), Northern Trust Corp (0.59%), Geode Capital Management LLC (0.57%), Geode Capital Management LLC (0.57%), Bank of New York Mellon Corp (0.28%) and Bank of America Corp DE (0.10%). Company insiders that own Pulse Biosciences stock include Maky Zanganeh, Mitchell E Levinson, Robert J Greenberg, Robert W Duggan and Thierry B Thaure. View Institutional Ownership Trends for Pulse Biosciences.
Which institutional investors are selling Pulse Biosciences stock?
Which institutional investors are buying Pulse Biosciences stock?
PLSE stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Geode Capital Management LLC, Rhumbline Advisers and Northern Trust Corp. Company insiders that have bought Pulse Biosciences stock in the last two years include Maky Zanganeh, Mitchell E Levinson and Robert W Duggan. View Insider Buying and Selling for Pulse Biosciences.
How do I buy shares of Pulse Biosciences?
Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pulse Biosciences' stock price today?
One share of PLSE stock can currently be purchased for approximately $19.44.
How big of a company is Pulse Biosciences?
Pulse Biosciences has a market capitalization of $402.19 million.
What is Pulse Biosciences' official website?
How can I contact Pulse Biosciences?
Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]
MarketBeat Community Rating for Pulse Biosciences (NASDAQ PLSE)
MarketBeat's community ratings are surveys of what our community members think about Pulse Biosciences and other stocks. Vote "Outperform" if you believe PLSE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLSE will underperform the S&P 500 over the long term. You may vote once every thirty days.
